LANTAK®30
LANTAK®30
To treat stomach and esophageal problems
Indication
LANTAK® is indicated in the treatment of:
- Gastro-oesophageal reflux disease.
- Peptic ulcer disease (duodenal and gastric ulcers).
- Zollinger-Ellison syndrome.
- Erosive Esophagitis.
- Acid related dyspepsia.
Composition
Each capsule of LANTAK® 30 contains:
- Lansoprazole (as enteric coated pellets) 30 mg.
Each capsule of LANTAK® 15 contains:
- Lansoprazole (as enteric coated pellets) 15 mg.
Dosage
- It is normally taken before food in the morning.
Gastro-oesophageal reflux disease:
- 30 mg daily by mouth for 4–8 weeks; thereafter maintenance therapy can be continued with 15 or 30 mg daily according to response.
Peptic ulcer disease:
- 30 mg once daily. Treatment is continued for 4 weeks for duodenal ulcer and 8 weeks for gastric ulcer.
- 15 mg daily has also been recommended as maintenance therapy for the prevention of relapse of duodenal ulcer.
Zollinger-Ellison syndrome:
- the initial dose is 60 mg daily, adjusted as required. Doses of up to 90 mg twice daily have been used.
Erosive Esophagitis:
- 30 mg once daily for up to 8 weeks.
In triple therapy regimens for elimination of Helicobacter pylori in peptic ulcer disease:
- effective regimens include LANTAK® 30 mg twice daily combined with Clarithromycin 250 mg twice daily and either Amoxicillin 1g twice daily or Metronidazole 400 mg twice daily; LANTAK®, Amoxicillin, and Metronidazole has also been used.
In patients with NSAID-associated ulceration:
- a dose of 15 or 30 mg daily for 4–8 weeks is recommended.
For the relief of acid-related dyspepsia:
- LANTAK® may be given in doses of 15 or 30 mg daily for 2–4 weeks.
Or as directed by the physician.
- Lansoprazole belongs to a class of antisecretory compounds,that do not exhibit anticholinergic or histamin H2-receptor antagonist properties ,but that suppress gastric acid secretion that acts by specific inhibition of the H+/K+-ATPase enzyme system.
- Lansoprazole may be useful in patients failing on a histamine H2-receptor antagonist (Cimetidine,Ranitidine, Famotidine or Nizatidine).
- Absorption of lansoprazole begins only after the pellets leave the stomach. Absorption is rapid, with peak plasma concentrations achieved about 1.5 hours after a dose by mouth; bioavailability is reported to be 80% or more even with the first dose.
- lansoprazole is extensively metabolized in the liver and excreted primarily in faces via bile,only about 15 to 30% of a dose is excreted in urine the plasma elimination half-life is around 1.4 to 2 hours but the duration of action is much longer.
Each capsule of LANTAK® 30 contains:
- Lansoprazole (as enteric coated pellets) 30 mg.
Each capsule of LANTAK® 15 contains:
- Lansoprazole (as enteric coated pellets) 15 mg.
LANTAK® is indicated in the treatment of:
- Gastro-oesophageal reflux disease.
- Peptic ulcer disease (duodenal and gastric ulcers).
- Zollinger-Ellison syndrome.
- Erosive Esophagitis.
- Acid related dyspepsia.
- Hypersensitivity to lansoprazole.
- Antacids and sucralfate may reduce the bioavailability of LANTAK®, and should not be taken within 1 hour of a dose of LANTAK®.
- Lansoprazole is thought to be a weak inducer of hepatic cytochrome P450, and may affect the pharmacokinetics of the drugs which are metabolized by this system.
- LANTAK® may interferes with the absorption of drugs where gastric pH is important determinant of bioavailability, (e.g. Ketoconazole, Iron salts, Ampicillin esters, and Digoxin).
- LANTAK® should not be administered during pregnancy and lactation unless strictly indicated according to the physician recommendations.
- LANTAK® has been well tolerated in both short-term and long-term treatment.
- The most commonly reported possibly or probably treatment-related a dverse event during maintenance therapy was diarrhea.
- It is normally taken before food in the morning.
Gastro-oesophageal reflux disease:
- 30 mg daily by mouth for 4–8 weeks; thereafter maintenance therapy can be continued with 15 or 30 mg daily according to response.
Peptic ulcer disease:
- 30 mg once daily. Treatment is continued for 4 weeks for duodenal ulcer and 8 weeks for gastric ulcer.
- 15 mg daily has also been recommended as maintenance therapy for the prevention of relapse of duodenal ulcer.
Zollinger-Ellison syndrome:
- the initial dose is 60 mg daily, adjusted as required. Doses of up to 90 mg twice daily have been used.
Erosive Esophagitis:
- 30 mg once daily for up to 8 weeks.
In triple therapy regimens for elimination of Helicobacter pylori in peptic ulcer disease:
- effective regimens include LANTAK® 30 mg twice daily combined with Clarithromycin 250 mg twice daily and either Amoxicillin 1g twice daily or Metronidazole 400 mg twice daily; LANTAK®, Amoxicillin, and Metronidazole has also been used.
In patients with NSAID-associated ulceration:
- a dose of 15 or 30 mg daily for 4–8 weeks is recommended.
For the relief of acid-related dyspepsia:
- LANTAK® may be given in doses of 15 or 30 mg daily for 2–4 weeks.
Or as directed by the physician.
- Symptomatic response to therapy with LANTAK® does not preclude the presence of gastric malignancy.
- Dosage should be reduced in hepatic impairment.
- LANTAK® Plastic jar of 14 capsules with a desiccant.
- LANTAK® Pack of 10 strips each strips containe 10 capsules.
- Store in a dry place below 30 °C, protected from light and humidity.